Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SYN-007
- Development stage
- Unknown
- Lead developer
- Theriva Biologics
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
SYN-007 is a delayed-release oral formulation of ribaxamase, a recombinant beta-lactamase enzyme developed by Synthetic Biologics (now Theriva Biologics). It is specifically designed to be co-administered with oral beta-lactam antibiotics, including those combined with beta-lactamase inhibitors like clavulanate. The enzyme acts locally within the gastrointestinal tract to degrade residual antibiotics that reach the colon, thereby protecting the commensal gut microbiome from disruption. This mechanism is intended to prevent antibiotic-associated complications such as *Clostridioides difficile* infection and the emergence of antimicrobial resistance, without interfering with the systemic absorption and efficacy of the antibiotic.
- Other names
- ribaxamase delayed-release
Beyond the preview
Go deeper on SYN-007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SYN-007.